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Background: Purpose of this study was to identify predictors of vaginal ulcer after CT based three-dimensional
image-guided high-dose-rate interstitial brachytherapy (HDR-ISBT) for gynecologic malignancies.
Methods: Records were reviewed for 44 female (14 with primary disease and 30 with recurrence) with
gynecological malignancies treated with HDR-ISBT with or without external beam radiation therapy. The HDR-ISBT
applicator insertion was performed with image guidance by trans-rectal ultrasound and CT.
Results: The median clinical target volume was 35.5 ml (2.4-142.1 ml) and the median delivered dose in equivalent
dose in 2 Gy fractions (EQD2) for target volume D90 was 67.7 Gy (48.8-94.2 Gy, doses of external-beam radiation
therapy and brachytherapy were combined). For re-irradiation patients, median EQD2 of D2cc for rectum and
bladder, D0.5cc, D1cc, D2cc, D4cc, D6cc and D8cc for vaginal wall was 91.1 Gy, 100.9 Gy, 260.3 Gy, 212.3 Gy, 170.1 Gy,
117.1 Gy, 105.2 Gy, and 94.7 Gy, respectively. For those without prior radiation therapy, median EQD2 of D2cc for rectum
and bladder, D0.5cc, D1cc, D2cc, D4cc, D6cc and D8cc for vaginal wall was 56.3 Gy, 54.3 Gy, 147.4 Gy, 126.2 Gy, 108.0 Gy,
103.5 Gy, 94.7 Gy, and 80.7 Gy, respectively. Among five patients with vaginal ulcer, three had prior pelvic radiation
therapy in their initial treatment and three consequently suffered from fistula formation. On univariate analysis,
re-irradiation and vaginal wall D2cc in EQD2 was the clinical predictors of vaginal ulcer (p = 0.035 and p = 0.025,
respectively). The ROC analysis revealed that vaginal wall D2cc is the best predictor of vaginal ulcer. The 2-year
incidence rates of vaginal ulcer in the patients with vaginal wall D2cc in EQD2 equal to or less than 145 Gy and
over 145 Gy were 3.7% and 23.5%, respectively, with a statistically significant difference (p = 0.026).
Conclusions: Re-irradiation and vaginal D2cc is a significant predictor of vaginal ulcer after HDR-ISBT for gynecologic
malignancies. Three-dimensional image-guided treatment planning should be performed to ensure adequate target
coverage while minimizing vaginal D2cc in order to avoid vagina ulcer.
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High-dose rate intracavitary brachytherapy (HDR-ICBT) is
an established method in the management of gynecological
malignancies, especially in cervical cancer. However, in pa-
tients with a narrow vagina, short uterine cavity, distal va-
ginal extension, and bulky tumors in which the optimal
dose distribution cannot be obtained by intracavitary* Correspondence: namuraka@ncc.go.jp
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reproduction in any medium, provided the orbrachytherapy (ICBT), interstitial brachytherapy (ISBT) is
employed. Also in patients with bulky postoperative cen-
tral pelvic recurrence, ISBT has proven to be effective
[1-5]. With the advent of image-guided brachytherapy it
has become possible to assess the dose volume histogram
(DVH) in brachytherapy. Several studies have validated
the D2cc as a predictor of rectal and bladder toxicities for
ICBT [6] or for ISBT [7]. D2cc of the rectum and bladder
have been introduced into daily clinical practice of
gynecological image-guided brachytherapy. However in
ICRU 38 vagina was not recognized as organ at riskral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and radioactive sources [8].
The purpose of this study was to retrospectively
analyze the incidence of vaginal morbidities after HDR-
ISBT for gynecological cancers and to find clinical and
dosimetric factors which affect the incidence of the vagi-
nal morbidities.
Methods
The inclusion criteria of this single institutional retro-
spective study were patients with gynecological malig-
nancies who were treated by HDR-ISBT with or without
external beam radiation therapy (EBRT) with a follow-
up length exceeding 6 months or more. Patients with
distant metastasis outside of pelvis were excluded from
current study. HDR-ISBT was applied for both primary
and salvage intents. Patients with superficial vaginal dis-
ease with thickness less than 5 mm were treated with
HDR-ICBT and did not treated by HDR-ISBT; therefore
these patients were not included in this analysis. Also
HDR-ISBT was not applied for those patients who had
distant metastasis or for those patients with far advanced
tumors which had not responded to EBRT performed
before HDR-ISBT. These patients were treated with
EBRT alone. One patient who succumbed to progressive
cancer in 5.5 months after ISBT was also excluded in
this analysis. The medical records of all patients with
gynecological malignancies treated with HDR-ISBT at
the National Cancer Center Hospital, Tokyo, Japan, be-
tween 2008 and 2011 were retrieved and 44 patients
were included in this study.
In the patients without prior pelvic irradiation, pelvic
EBRT was delivered before HDR-ISBT. The common
EBRT portals were whole pelvic irradiation including
gross tumor volume (GTV) with adequate margin as
well as the pelvic lymph nodes basin up to the level of
the common iliac (L4/5 junction). If the tumor involved
the lower third of the vagina, or there were clinically
palpable inguinal nodes, inguinal regions were also in-
cluded in the EBRT portals. The initial 20-40 Gy was de-
livered to the whole pelvis with a 4-fields box technique
and then pelvic irradiation was administered with a cen-
tral shield being employed to reduce exposure of organs
at risk (OAR). The total dose delivered to the pelvic side
wall was up to 50 Gy in a conventional fractionation. In
patients with a history of prior pelvic radiation therapy
or in feeble elderly patients, no EBRT or smaller EBRT
fields with a reduced total dose were employed. HDR-
ISBT was basically performed after the central shield
was inserted. However for those patients treated without
EBRT, HDR-ISBT was applied as solitary radiotherapy
modality. The detailed procedure of gynecological HDR-
ISBT was described elsewhere [9]. In brief, transperineal
needle applicator insertion was performed under eithergeneral or local anesthesia with the patients in lithotomy
position and guided by trans-rectal ultrasound (TRUS)
or CT which can be taken with the patients lying in lith-
otomy position with the applicators in place. For ad-
vanced large disease, a Syed-Neblett perineal template
(Best Medical International, Inc., Springfield, VA) was
used in order to sufficiently cover lateral disease extent.
For rather localized small disease, with limited parame-
trial and/or paracolpial invasion, free-hand needle appli-
cator insertion with or without a vaginal applicator was
used with fewer needles inserted compared to the Syed-
Neblett perineal template. Treatment planning was per-
formed with brachytherapy planning system (Oncentra®
Nucletron, Veenendaal, The Netherlands) using CT im-
ages taken by the large bore CT simulator (Aquilion
LG®, Toshiba, Tokyo, Japan), which allows imaging of
the patients in lithotomy position. Although different
applicator was used throughout the patients, the calcu-
lation method applied was the same. The clinical target
volume (CTV) was defined based on the CT image obtained
after needle insertion, as well as physical examination imme-
diately before needle insertion, the intra-operative TRUS
image and the most recent MRI were also taken into ac-
count. Reference points were set on the surface of CTV and
prescribed dose was delivered to those points. HDR-ISRT
treatment plan was calculated initially by geometrical
optimization or volume optimization and then manual
graphical modification was followed to enclose the CTV by
the prescription dose while minimizing high dose to OAR.
The median HDR-ISBT dose was 24 Gy (range, 18-54 Gy),
and median HDR-ISBT dose per fraction was 6 Gy
(range, 4-6 Gy). HDR-ISBT was performed twice daily
with each fraction 6 hours apart. HDR-ISBT was per-
formed with MicroSelectron HDR (Nucletron, Veenen-
daal, The Netherlands) using Ir-192.
At the discretion of the attending physician, weekly
CDDP 40 mg/m2 was used in 10 patients concurrently
with EBRT. In general, patients with bulky disease, good
performance status and adequate organ function were
selected for the candidate for the administration of con-
current chemoradiation. Patients were seen in follow up
1 week after HDR-ISBT for a skin check, then every 1-2
months for 2 years, every 3-4 months for 5 years, and
every 6-12 months thereafter.
When adding doses of EBRT, HDR-ISBT, and HDR-
ICBT, we used the equivalent dose in 2 Gy fractions
(EQD2) according to the LQ model [10,11]. For re-
irradiated patients, prior central pelvic EBRT doses were
also added to EQD2 for OARs. For those who had prior
HDR-ICBT without DVH parameters of OARs because
of lack of three dimensional dose calculations, it was dif-
ficult to estimate EQD2 for OARs. Therefore, prescribed
dose for tumor in EQD2 (α/β = 10) was converted to
EQD2 for late responding tissue (α/β = 3) and added
Table 1 Patients characteristics (n = 44)
Patients (n)
Median age (years, range) 56 (25-89)





Primary therapy 14 (31.8%)
Cervical cancer 4 (9.1%)
Vaginal cancer 10 (22.7%)
Salvage therapy 30 (68.2%)
Post ope regidual tumor 5 (11.4%)
Post ope recurrent tumor 21 (47.7%)
Post RT recurrent tumor 4 (9.1%)
Histology Scc 25 (56.8%)
Adeno 16 (36.4%)
Others 3 (6.8%)
Prior pelvic RT* Yes 8 (18.2%)
No 36 (81.8%)
Median tumor size (cm, range) 3.6 (1.0-8.0)
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current RT was not taken into consideration in this
analysis.
Rectum and bladder were contoured as a whole organ.
Vaginal wall was extracted with a thickness of 4 mm on
all CT images according to the Vienna group [12]. As
for rectum and bladder, dosimetric parameter of D2cc
was used because these values have been validated by
several studies [6-8]. On the other hand, there is no vali-
dated parameter for vaginal dose; therefore D0.5cc, D1cc,
D4cc, D6cc, and D8cc were calculated along with D2cc for
vaginal wall dose volume parameters.
Late vaginal morbidities were retrospectively evaluated
according to LENT-SOMA scales [13]. Because morbid-
ity scores were evaluated retrospectively in this study,
we focused on only vaginal ulcer which could be regarded
as one of the severest symptoms and could be retrieved
accurately from medical records.
Student’s unpaired t-test was used to compare the
continuous variables and Pearson’s chi-square test to
compare categorical variables. A p value of < 0.05 was
considered as statistically significant. In addition, cal-
culation of the area under the curve (AUC) of receiver
operating characteristics (ROC) was used to determine
the most predictive dosimetric parameter of vaginal
ulcer. The predictive values of parameters were evalu-
ated based on the AUC. The optimal threshold for
each parameter was defined as the point yielding the
minimal value for (1 - sensitivity) 2 + (1 – specificity) 2,
which is the point on the ROC curve closest to the
upper left-hand corner [14]. The obtained cutoff point
was used for dividing patients into two groups and the
incidences of vaginal ulcer were calculated by Kaplan-
Meier method with the difference evaluated by log-lank
test. All statistical analyses were performed using SPSS
Statistics version 18.0 (SAS Institute, Tokyo, Japan).
This retrospective study was approved by the institu-
tional review board of the National Cancer Center.
Results
There were 44 patients who met the eligibility criteria
and 36 patients were alive at the time of the analysis
(May 2012). The median follow-up length of living pa-
tients was 18.3 months (range, 7.6-39.5 months). The
pretreatment characteristics of the 44 patients included
in this study are summarized in Table 1. Median age was
56 years (range, 25-89 years). HDR-ISBT was applied as
the primary therapy in 14 patients (31.8%) and as the
salvage therapy in 30 patients (68.2%). Eight patients
(18.2%) had previously received pelvic irradiation, in the
form of EBRT and/or ICBT. Twenty four patients were
treated with Syed-Neblett perineal template, 17 with
free-hand with vaginal applicator and three with free-
hand without vaginal applicator. Treatment details aresummarized in Table 2. Ten patients underwent concur-
rent chemotherapy. In most cases HDR-ISBT dose per
fraction was 6 Gy. Median total EQD2 of CTV D90 was
67.7 Gy. Median EQD2 of D2cc for rectum and bladder
was 60.8 Gy and 58.1 Gy, respectively. Median EQD2 of
D0.5cc, D1cc, D2cc, D4cc, D6cc, and D8cc for vaginal wall
were 210.7 Gy, 167.3 Gy, 131.5 Gy, 111.6 Gy, 100.0 Gy,
and 83.2 Gy, respectively. Table 3 shows EQD2 of rec-
tum, bladder and vaginal wall for the patients with or
without prior pelvic radiation therapy. For re-irradiation
patients, median EQD2 of D2cc for rectum and bladder,
D0.5cc, D1cc, D2cc, D4cc, D6cc and D8cc for vaginal wall
was 91.1 Gy, 100.9 Gy, 260.3 Gy, 212.3 Gy, 170.1 Gy,
117.1 Gy, 105.2 Gy, and 94.7 Gy, respectively. For those
without prior radiation therapy, median EQD2 of D2cc
for rectum and bladder, D0.5cc, D1cc, D2cc, D4cc, D6cc and
D8cc for vaginal wall was 56.3 Gy, 54.3 Gy, 147.4 Gy,
126.2 Gy, 108.0 Gy, 103.5 Gy, 94.7 Gy, and 80.7 Gy, re-
spectively (Table 3). In EQD2 of D2cc for rectum, bladder
and vaginal wall the difference was statistically signifi-
cant (p < 0.001, p < 0.001, and p = 0.001, respectively).
As for late morbidities of vagina, five patients experi-
enced vaginal ulcer after HDR-ISBT. All of vaginal ulcer
occurred within two years after completion of the HDR-
ISBT. Patient characteristics and objective/management
Table 3 DVH parameters for bladder and vaginal wall with
or withour prior radiation therapy
Prior pelvic
RT∫ (+) (n = 8)
Prior pelvic










100.9 (69.7-120.3) 54.3 (7.3-82.7) < 0.001*
Median vaginal wall D0.5cc
†
(EQD2*, Gy, range)
260.3 (59.9-349.3) 147.4 (47.9-267.3) 0.109
Median vaginal wall D1cc
†
(EQD2*, Gy, range)
212.3 (58.2-277.5) 126.2(33.6-182.7) 0.013
Median vaginal wall D2cc
†
(EQD2*, Gy, range)
170.1 (56.6-247.5) 108.0 (31.7-150.9) 0.001*
Median vaginal wall D4cc
†
(EQD2*, Gy, range)
117.1 (34.0-200.8) 103.5 (39.1-139.4) 0.139
Median vaginal wall D6cc
†
(EQD2*, Gy, range)
105.2 (33.0-173.7) 94.7 (20.4-138.7) 0.097
Median vaginal wall D8cc
†
(EQD2*, Gy, range)
94.7 (32.4-144.4) 80.7 (10.3-130.4) 0.105
∫RT: radiation therapy.
*EQD2: equivalent dose in 2 Gy fractions.
†D0.5cc, D1cc, D2cc, D4cc, D6cc, D8cc: most exposed 0.5, 1, 2, 4, 6, and 8 cm3
of tissue.
Table 2 Treatment details (n = 44)
Median range
Central pelvic dose of EBRT* (Gy) 30 (0-50)
No. of needles used in HDR-ISBT† 15 (5-29)
HDR-ISBT† fractions 4 (3-9)
HDR-ISBT† dose per fraction (Gy) 6 (4-6)
CTV†† (ml) 35.1 (2.4-142.1)
CTV†† D90 in EQD2
|| (Gy) 67.7 (48.8-94.2)
Rectum D2cc
¶ in EQD2
|| (Gy) 60.8 (30.5-114.3)
Bladder D2cc
¶ in EQD2
|| (Gy) 58.1 (7.3-120.3)
Vaginal wall D0.5cc
¶ in EQD2
|| (Gy) 210.7 (51.5-468.1)
Vaginal wall D1cc
¶ in EQD2
|| (Gy) 167.3 (49.9-352.1)
Vaginal wall D2cc
¶ in EQD2
|| (Gy) 131.5 (43.7-294.4)
Vaginal wall D4cc
¶ in EQD2
|| (Gy) 111.6 (34.0-200.8)
Vaginal wall D6cc
¶ in EQD2
|| (Gy) 100.0 (20.4-173.7)
Vaginal wall D8cc
¶ in EQD2




*EBRT: external beam radiation therapy.
†HDR-ISBT: high-dose-rate interstitial brachytherapy.
††CTV: clinical target volume.
||EQD2: equivalent dose in 2 Gy fractions.
¶D0.5cc, D1cc, D2cc, D4cc, D6cc, D8cc: most exposed 0.5, 1, 2, 4, 6 and 8 cm3
of tissue.
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summarized in Table 4. Two patients had superficial
and > 1 cm2 vaginal ulcer and three had vaginal fistula
(two vesicovaginal fistulae and one vesicovaginorectal
fistula). Three out of the five patients had prior pelvic ir-
radiation and the interval between prior pelvic irradi-
ation and secondary pelvic irradiation was 15, 27, and 40
months, respectively. All of the three patients with vagi-
nal fistula received hyperbaric oxygen therapy without
success. Two underwent surgical intervention (one total
cystectomy for massive hematuria and one nephrostomy)
for their vesicovaginal fistula, while one was followed up
conservatively with a persistent vesicovaginal fistula. The
other two patients with grade 2 vaginal ulcer were treated
conservatively. The overall 2-year actuarial incidence of
vaginal ulcer was 11.4%; 37.5% for re-irradiation patients
and 5.6% for those without prior radiation therapy
(Figure 1a). Comparison of dose-volume parameters of
the vaginal wall is shown in Table 5 for the patient
with and without vaginal ulcer. It was shown that the
incidence of vaginal ulcer in the patients with prior
pelvic irradiation was statistically higher than that of
the patients without prior pelvic irradiation (p = 0.035).
It was also shown that the mean EQD2 of vaginal wall
D2cc of patients with or without vaginal ulcer was sta-
tistically different (p = 0.025). There was no relation-
ship between administration of concurrent chemotherapy
and manifestation of vaginal ulcer (p = 0.256), number of
needles used in HDR-ISBT (p = 0.293) nor bladder D2cc
EQD2 (p = 0.091). The ROC analysis revealed that vaginal
wall D2cc was the best dosimetric parameter predicting the
incidence of vaginal ulcer and the cutoff value of 145 Gy
in vaginal wall D2cc provided the lowest p value in log-
rank test (Table 6). Figure 1b shows Kaplan-Meyer curve
for the incidence of vaginal ulcer stratified by vaginal wall
D2cc 145 Gy in EQD2. The 2-year incidence rates of vagi-
nal ulcer in the patients with vaginal wall D2cc equal to or
less than 145 Gy in EQD2 and over 145 Gy were 3.7% and
23.5%, respectively, with a statistically significant differ-
ence (p = 0.026).
Discussion
Although the Manchester method of ICBT for the cer-
vical cancer was developed to avoid the occurrence of
radiation induced vaginal ulcer and necrosis, vaginal
ulcer is now very rarely encountered because vaginal
wall is relatively radioresistant and typical ICBT delivers
radiation dose less than the tolerance of the relatively
radioresistant vaginal wall. In a retrospective study of
cervical cancer patients using EBRT and the film based
low-dose rate (LDR) brachytherapy, Samuel et al. showed
that vaginal tolerance dose was above 150 Gy [15]. In re-
cent advancement of image guided brachytherapy (IGBT),
rectum and bladder doses were recommended to be

























1 40 Cervix WPRT† 45 Gy/25fr +
EBRT†† boost 15 Gy/5fr
27 HDR-ISBT* 36 Gy/9fr 272.1/202.6/169.1 4 4
2 51 Cervix None None WPRT† 30 Gy/15fr +
CS|| 20 Gy/10fr +
HDR-ISBT* 24 Gy/4fr
215.2/171.8/145.4 4 3
3 64 Corpus None None WPRT† 30 Gy/15fr +
HDR-ISBT* 30 Gy/5fr
196.6/141.5/109.1 2 1
4 64 Cervix WPRT† 40 Gy/20fr +
CS 10 Gy/5 + HDR-ICBT
18 Gy/3fr
40 HDR-ISBT* 48 Gy/8fr 465.4/352.1/294.4 2 1
5 67 Cervix WPRT† 50 Gy/50fr +
HDR-ICBT 12 Gy/3fr
15 HDR-ISBT* 42 Gy/7fr 234.0/211.1/193.5 4 3
*HDR-ISBT: high-dose-rate interstitial brachytherapy.
†WPRT: whole pelvis radiation therapy.
††EBRT: external beam radiation therapy.
||CS: radiation therapy with center shielding.
¶LENT-SOMA: Late Effects of Normal Tissues - Subjective, Objective, Management, Analytic.
#D0.5cc, D1cc, D2cc: most exposed 0.5, 1 and 2 cm3 of tissue.
##EQD2: equivalent dose in 2 Gy fractions.
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vagina was not mentioned as OAR [9]. In the GEC-
ESTRO working group (II) or American Brachytherapy
Society guidelines, vagina was taken into consideration for
OAR but it was stated that the vaginal dose volume pa-
rameters still need to be defined [16,17]. Dimopoulos
et al. reported clinical result of primary vaginal cancer
treated with IGBT and they experienced two vaginal fistu-
lae and one periurethral necrosis. However they did not
specify DVH parameters of vaginal wall with vaginalFigure 1 Cumulative incidene of vaginal ulcer. a: Cumulative incidence
vaginal wall D2cc 145 Gy in EQD2.complication [18]. Lee et al. reported in detail the toxicity
analysis of CT based HDR-ISBT for gynecologic malig-
nancies. They reported that D2cc for the rectum was a
reliable predictor of late rectal complication; however
because of limited number of events it was not able to
explore the DHV parameters for vaginal complication
[5]. Recently, Vienna group tried to find out DVH pa-
rameters that correlate with vaginal late morbidities
but vaginal D2cc did not relate with the vaginal mor-
bidities [12]. The calculation method was the same asof vaginal ulcer. b: Cumulative incidence of vaginal ulcer stratified by
Table 5 Clinical predictors of vaginal ulcer
Characteristic Vaginal ulcer (+) (n = 5) Vaginal ulcer (-) (n = 39) p value






Median number of needles used in HDR-ISBT∫ (range) 14 (10-24) 15 (5-29) 0.293
Median CTV† (ml, range) 54.7 (17.7-114.0) 34.7 (2.4-142.1) 0.271
Median rectum D2cc
†† (EQD2
||, Gy, range) 84.2 (34.0-100.7) 57.9 (30.5-114.3) 0.118
Median bladder D2cc
†† (EQD2
||, Gy, range) 69.3 (37.4-113.5) 57.7 (7.3-120.3) 0.091
Median vaginal wall D0.5cc
†† (EQD2
||, Gy, range) 206.4 (106.6-349.3) 149.4 (47.9-310.1) 0.243
Median vaginal wall D1cc
†† (EQD2
||, Gy, range) 169.1 (91.6-277.5) 127.9 (33.6-220.8) 0.096
Median vaginal wall D2cc
†† (EQD2
||, Gy, range) 152.5 (71.1-247.5) 109.0 (31.7-201.9) 0.025*
Median vaginal wall D4cc
†† (EQD2
||, Gy, range) 115.5 (83.8-200.8) 110.6 (34.0-153.2) 0.152
Median vaginal wall D6cc
†† (EQD2
||, Gy, range) 102.5 (60.4-173.7) 99.5 (20.4-146.3) 0.266
Median vaginal wall D8cc
†† (EQD2
||, Gy, range) 82.0 (47.6-144.4) 84.3 (10.3-140.3) 0.511
*RT: radiation therapy.
∫HDR-ISBT.
†CTV: clinical target volume.
||EQD2: equivalent dose in 2 Gy fractions.
††D0.5cc, D1cc, D2cc, D4cc, D6cc, D8cc: most exposed 0.5, 1, 2, 4, 6, and 8 cm3 of tissue.







































0.559 ≤75 Gy 5.6 0.323
>75 Gy 15.4
*AUC: area under the curve.
†ROC: receiver operator characteristic.
††EQD2: equivalent dose in 2 Gy fractions.
||D0.5cc, D1cc, D2cc, D4cc, D6cc, D8cc: most exposed 0.5, 1, 2, 4, 6, and 8 cm3
of tissue.
¶Cutoff refers to the most predictive value from the AUC of ROC curve.
# Univariate analysis by log-rank test.
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ICBT/ISBT and normalized to 2 Gy per fraction (EQD2)
using the linear-quadratic model with α/β of 3 Gy for the
vaginal morbidities [10-12,16]. The difference between
Vienna group and the current study was that there were
more patients with severe vaginal morbidities in the
current study, presumably because there were more pa-
tients who received re-irradiation and current study ex-
cluded the patients treated with HDR-ICBT. HDR-ISBT
delivers higher dose to the vaginal wall than HDR-ICBT
because the multiple needle applicators directly contact
vaginal wall. According to the current results, after vaginal
wall D0.5cc, D1cc, D2cc, D4cc, D6cc, and D8cc having been
compared, vaginal wall D2cc was found to be the most
relevant DVH parameter predicting the incidence of vagi-
nal ulcer. ROC analysis also showed that vaginal wall D2cc
of 145 Gy in EQD2 can be used as clinical cutoff dose pre-
dicting vaginal ulcer. This figure is quite similar to the
vaginal tolerance dose of 150 Gy derived from a retro-
spective study of LDR brachytherapy which was previ-
ously mentioned [15]. The current report is the first
one concerning about vaginal DVH parameter and
complication using modern era of three-dimensional
image-guided brachytherapy. It was also found in this
study that the history of prior pelvic irradiation was
another significant predictive factor for vaginal ulcer
(Table 5). Lee et al. reported a patient with colovaginal
fistula with previous EBRT [5,7]. As shown in Table 3,
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in patients with prior pelvic irradiation than those
without prior pelvic irradiation. However both rectum
and bladder D2cc was not in itself a significant prog-
nostic factor for vaginal ulcer and could not be used as
a surrogate indicator (Table 5).
There were several limitations in this study. Contour-
ing of the vagina was not based on MRI but CT, which
is inferior to MRI in tissue contrast. However because
41 out of 44 patients were inserted either cylinder or
mold into their vagina, contouring of vagina was consid-
ered to be precise. The time interval between the prior
pelvic RT and HDR-ISBT was not taken into consider-
ation for the calculation of the total dose for OARs.
Additionally, this study was a retrospective study with
small number of patients with heterogeneous tumor ori-
gin, heterogeneous treatment applied, small number of
events, and with short follow-up period. Therefore we
should be cautious about the results of the current
study. However even tumor origin differed greatly in
current cohorts of study, it is considered to be feasible
because the main concern in current study was focused
on only the vaginal toxicity.
It should be stressed that with the introduction of
HDR-ISBT in gynecological malignancies and increment
of vaginal dose, vaginal tolerance dose must be taken
into consideration. Further discussion and validation of
vaginal DVH parameters in image-guided brachytherapy
in a multicenter prospective study is needed.Conclusions
The DVH parameters for vagina are essential for treat-
ment planning and optimization in image based HDR-
ISBT in gynecological malignancies. Vaginal wall D2cc in
EQD2 should be monitored and be kept under 145 Gy in
order to avoid vaginal ulcer. Also in patients with prior
pelvic irradiation, vaginal wall dose including the prior
radiation dose should be kept lower than 145 Gy.Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
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